This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2543 V3 | October 2024

Prescribing information and adverse event reporting statement can be found in the footer

This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2543 V3 | October 2024

Prescribing information and adverse event reporting statement can be found in the footer

Add to favourites
For Healthcare Professionals
Slenyto® Therapeutic Bulletin

A succinct summary of the evidence-base for Slenyto® (paediatric prolonged-release melatonin) for the treatment of insomnia in children and adolescents with Autistic Spectrum Disorder and/ or Smith-Magenis Syndrome.

PRODUCT: Slenyto®

Related Education and Training items